GSK press releases
Follow
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Zejula is the only monotherapy available for women who do not have a BRCA mutation.
